NRX Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET

Company Participants

Matthew Duffy - Chief Business Officer

Stephen Willard - Chief Executive Officer

Jonathan Javitt - Founder & Chief Scientist

Richard Narido - Chief Financial Officer & Treasurer

Conference Call Participants

Ed Woo - Ascendiant Capital

Operator

Thank you for standing by. This is the conference operator. Welcome to NRX Pharmaceuticals' Third Quarter 2023 Earnings Conference Call. As a reminder, all participants are in listen-only mode. The conference is being recorded. After the presentation, there will be an opportunity to questions. [Operator Instructions]

I would now like to turn the conference over to Mr. Matthew Duffy, Chief Business Officer. Please go ahead.

Matthew Duffy

Thank you, Ashia. Welcome everyone. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under US Federal Securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations.

Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC.

The forward-looking statements made during this call speak only as of the date hereof and the company undertakes no obligation to update or revise the forward-looking statements.

Information presented on this call is contained in the press release issued earlier today and in the company's Form 10-Q that was filed earlier today, which may be accessed from the Investor's page of the NRX Pharmaceuticals, Inc. website.

Joining me on the call are Stephen Willard, our Chief Executive Officer; Dr. Jonathan Javitt, our Founder and Chief Scientist; and Richard Narido, Chief Financial Officer and Treasurer.

Stephen and Jonathan will provide a summary of the company's progress. Richard will review the company's financial results, and then Stephen will review upcoming milestones before making closing comments. Following their prepared remarks, we will address investor questions.

I'll now turn the call over to Stephen. Steve?

Stephen Willard

Thank you, Matt. Good afternoon everyone and thank you for joining us. The third quarter represents a potential turning point for our company as we are approaching our clinical trial enrollment goals for our partnered foundation product, NRX-101, while opening new clinical initiatives in chronic pain, urinary tract infection, and NRX-100 for suicidal depression.

We expect four potential upcoming milestones. First, our core clinical trial of NRX-101 for treatment-resistant bipolar depression with suicidality.